• Financial growth momentum: First-quarter revenue increased by 26% year-on-year, driving EBITDA positive to Rs 107 crore, with the base business projected to sustain at least 20% growth over the next 12 to 18 months.
• Long-term growth guidance: Management expects rapid growth to commence in FY28, followed by hockey-stick growth and substantial margin expansion from FY29 onward.
• R&D investment plans: R&D expenditures will remain at 10% to 12% of revenue over the next 3 to 5 years to support global clinical trials for Emrok, Miqnaf, and WCK 77.
• ZayNICH revenue target: ZayNICH is targeted to achieve peak sales of $1.5 to $2 billion during its patent lifecycle, with subsequent new molecule launches phased to allow adequate scientific education for clinicians.